Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;25(5):647-656.
doi: 10.1007/s40291-021-00548-0. Epub 2021 Jul 22.

Piflufolastat F 18: Diagnostic First Approval

Susan J Keam  1
Affiliations
Review

Piflufolastat F 18: Diagnostic First Approval

Susan J Keam. Mol Diagn Ther. 2021 Sep.

Abstract

Piflufolastat F 18 (PYLARIFY®) is an 18F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA). Piflufolastat F 18 was approved in the USA on 27 May 2021 for PET of PSMA positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate specific antigen (PSA) level. This article summarizes the milestones in the development of piflufolastat F 18 leading to this approval as a radioactive diagnostic agent in prostate cancer.

PubMed Disclaimer

References

    1. Luining WI, Meijer D, Dahele MR, et al. Nuclear imaging for bone metastases in prostate cancer: the emergence of modern techniques using novel radiotracers. Diagnostics (Basel). 2021;11(1):117. - DOI
    1. Zimmerman ME, Meyer AR, Rowe SP, et al. Imaging of prostate cancer with positron emission tomography. Clin Adv Hematol Oncol. 2019;17(8):455–63. - PubMed
    1. Jansen BHE, Yaqub M, Voortman J, et al. Simplified methods for quantification of (18)F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. 2019;60(12):1730–5. - DOI
    1. Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: a systematic review. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20194886 . - DOI - PubMed - PMC
    1. Keegan NM, Bodei L, Morris MJ. Seek and find: current prospective evidence for prostate-specific membrane antigen imaging to detect recurrent prostate cancer. Eur Urol Focus. 2021;7(2):267–78. - DOI

LinkOut - more resources